Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Unprecedented decision opens the way for the launch of Strangvac in Iceland
Intervacc AB (publ) announces that Strangvac®, the company’s innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially lethal infection caused by Streptococcus equi, is the most frequently diagnosed...Intervacc publishes the 2025 Annual Report
Intervacc AB (publ) announces that the company’s 2025 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the company’s website intervacc.com....Notice of Annual General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 13 May 2026 at 3.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. Participation at the AGM...Intervacc announces breakthrough protection against Streptococcus suis infection in piglets
Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating sows and transferring maternal immunity to piglets. The...Year-end report January – December 2025
The Group in summary 01/10/25 01/10/24 Full year Full year -31/12/25 -31/12/24 2025 2024 Net sales 3 123 4 127 20 087 11 787 Operating loss -36 377 -18 505 ...Nyhetstjänster
